Clinical Trial Update: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating secukinumab 300 mg for Thyroid Eye Disease (Graves' orbitopathy) was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy
• Thyroid Eye Disease

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Status: TERMINATED | Results posted: 2025-01-09